Sodium stibogluconate

Drug Profile

Sodium stibogluconate

Alternative Names: Lenocta; SSG; VQD-001

Latest Information Update: 05 Dec 2011

Price : $50

At a glance

  • Originator Greenwich Therapeutics
  • Developer University of Texas M. D. Anderson Cancer Center; VioQuest Pharmaceuticals; Walter Reed Army Medical Center
  • Class Antineoplastics; Antiprotozoals; Small molecules
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous leishmaniasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cutaneous leishmaniasis; Solid tumours

Most Recent Events

  • 12 Feb 2010 A phase I/II trial in Advanced malignancies completed in USA
  • 10 Oct 2007 Clinical data added to the adverse events and Cancer pharmacodynamics sections
  • 10 Oct 2007 VioQuest completes enrolment in its phase I trial for Solid tumours in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top